Resilient Performance and Strategic Growth Drive Buy Rating for Harvard Bioscience Amid Market Challenges

Benchmark Co. analyst Bruce Jackson maintained a Buy rating on Harvard Bioscience today and set a price target of $2.00.

Bruce Jackson has given his Buy rating due to a combination of factors impacting Harvard Bioscience. Despite the challenging market conditions in the healthcare sector, particularly in the Life Science Tools segment, Harvard Bioscience has shown resilience. The company exceeded revenue expectations in the second quarter, achieving $20.5 million against a consensus estimate of $18.8 million, and managed to increase its Adjusted EBITDA slightly year-over-year to $1.5 million.
Furthermore, the company’s strategic focus on MEAs and Organoids in the Americas has shown sequential growth, and European sales have benefited from increased pharma sales. Although there are challenges, such as tariff concerns in APAC and budget uncertainties in academic markets, the potential for sector recovery and improved profitability in the future supports the Buy rating. Bruce Jackson’s price target for HBIO is set at $2 per share, reflecting a belief in the company’s ability to capitalize on easier comparisons and profitability improvements by 2026.

Jackson covers the Healthcare sector, focusing on stocks such as Harvard Bioscience, Belite Bio, Inc. ADR, and CapsoVision, Inc.. According to TipRanks, Jackson has an average return of -18.5% and a 30.61% success rate on recommended stocks.